PLos One:D-二聚体水平可以预测非小细胞肺癌术后的预后

2020-01-17 xiangting MedSci原创

在CT为实性肿瘤改变的NSCLC患者中, D-二聚体水平高预示生存率差和早期复发。

癌细胞经常调节癌症患者的凝血和纤维蛋白溶解。血浆二聚纤溶酶片段DD-二聚体)已被报道为多种癌症类型的预后标志物,其中包括非小细胞肺癌NSCLC)。但是,血浆D-二聚体水平与周围小NSCLC之间的关系尚不清楚。

研究回顾性分析了接受根治性手术的362NSCLC患者。排除术前接受抗凝治疗或没有术前D-二聚体数据的患者。其余235例患者被分为D-二聚体升高组(超过1.0μg/mL)(HDD组,n = 47)和D-二聚体正常组(NDD组,n = 188),并对其临床特征、计算机断层扫描(CT)结果、病理结果和临床结局进行了研究。

HDD组的平均D-二聚体水平为2.49±2.58μg/mlNDD组为0.42±0.23μg/mlHDD组的特征是以男性为主、年龄较大、胸部CT为纯实性改变、病理有血管浸润以及肿瘤大部分为实性。与NDD组相比,HDD组的总生存率、无病生存率和疾病特异性生存率较差(分别为p<0.001<0.001<0.001)。在IA期疾病中也观察到了这些生存率特征。当肿瘤在CT上为磨玻璃样混浊时,生存率没有明显差异。

CT为实性肿瘤改变的NSCLC患者中, D-二聚体水平高预示生存率差和早期复发。

原始出处:

Yuki Shiina. The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer. PLos One. December 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1790377, encodeId=a10d1e9037757, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Apr 10 08:44:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059864, encodeId=c95c2059864ad, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Jan 30 01:44:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950383, encodeId=173519503835e, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Oct 20 21:44:00 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310861, encodeId=c3d9131086166, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun Jan 19 09:44:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1790377, encodeId=a10d1e9037757, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Apr 10 08:44:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059864, encodeId=c95c2059864ad, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Jan 30 01:44:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950383, encodeId=173519503835e, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Oct 20 21:44:00 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310861, encodeId=c3d9131086166, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun Jan 19 09:44:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1790377, encodeId=a10d1e9037757, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Apr 10 08:44:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059864, encodeId=c95c2059864ad, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Jan 30 01:44:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950383, encodeId=173519503835e, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Oct 20 21:44:00 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310861, encodeId=c3d9131086166, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun Jan 19 09:44:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
    2020-10-20 hxj0117
  4. [GetPortalCommentsPageByObjectIdResponse(id=1790377, encodeId=a10d1e9037757, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Apr 10 08:44:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059864, encodeId=c95c2059864ad, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Jan 30 01:44:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950383, encodeId=173519503835e, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Oct 20 21:44:00 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310861, encodeId=c3d9131086166, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun Jan 19 09:44:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]

相关资讯

Sci Rep:非小细胞肺癌患者全身治疗对脑转移的影响

总之,接受TT作为一线治疗患者的脑转移总累积发生率明显高于CC治疗患者。

PNAS:探究“致命”肺癌,科学家发现CRISPR-Cas9系统新应用

p107和p130是视网膜母细胞瘤蛋白家族的成员,二者都在大约6%的人类SCLC肿瘤中反复突变。研究人员将CRISPR-Cas9系统改编为成熟的SCLC小鼠模型,通过模拟Trp53 / Rb1中p107和p130缺失对该方法在SCLC中的可行性进行了验证。

NEJM:Osimertinib一线治疗晚期非小细胞肺癌

研究认为,相比于第一代靶向药物,Osimertinib一线治疗EGFR突变的晚期非小细胞肺癌可显著延长患者总生存期

Thorax:I期非小细胞肺癌肺叶切除术与立体定向消融放疗的治疗后生存率差异

这项分析表明,与SABR患者相比,接受肺叶切除术的患者生存率更高;但是,研究发现接受SABR的患者有明显的治疗延迟,这可能是导致这种治疗方案长期预后较差的原因。

2019年盘点:非小细胞肺癌少见/罕见驱动基因变异治疗进展

作者: 刘晓晴  解放军总医院第五医学中心 李晓燕  首都医科大学附属北京天坛医院     伴随着北京洋洋洒洒飘落的雪花,送别圣诞,即将迎来2020年元旦,肿瘤治疗的林林总总又进入了年终盘点时刻。话说今年是肺癌治疗进展之小年,然与已“大红大紫”的高频驱动基因靶向治疗和“如日中天”的免疫治疗相比,几年前还乏人问津,驻足不前

Opdivo & Yervoy联合疗法在日本寻求治疗不可切除、晚期或复发性非小细胞肺癌

ONO制药和Bristol-Myers Squibb近日宣布,两家公司已提交了Opdivo(nivolumab)联合Yervoy(ipilimumab)治疗不可切除、晚期或复发性非小细胞肺癌(NSCLC)的申请。